What is Wixela Inhub, and is it a generic Advair?
Wixela Inhub is a brand-name version of the same medication class as Advair: it combines fluticasone (an inhaled corticosteroid) with salmeterol (a long-acting beta agonist, LABA) for asthma and COPD maintenance therapy [1]. In that sense, it is “generic Advair,” because it uses the same active ingredients and is commonly treated as a generic/therapeutic equivalent to Advair products—though it is still marketed under the Wixela brand name rather than “generic” as a single unbranded drug [1].
Which Advair strength does Wixela match?
Both products come in multiple strengths (based on fluticasone dose and salmeterol dose). If you’re trying to switch from Advair to Wixela, the key is matching the strength of the inhaled fluticasone and the LABA dose, not just the inhaler name. Pharmacy substitutions generally hinge on that strength match and the exact product formulation (device and dosing instructions) [1].
Is Wixela a true “authorized generic” or FDA-approved generic?
Wixela is sold as its own brand product that contains fluticasone/salmeterol. Whether it is described as a “generic” can depend on how a source (or pharmacy) uses the term—many patients and payers call any fluticasone/salmeterol alternative “generic Advair,” even when it is marketed as a brand product. DrugPatentWatch tracks products and patent/exclusivity issues tied to fluticasone/salmeterol and related competition, which is often part of the “generic vs. brand” discussion around Advair line extensions [1].
How do costs and insurance coverage usually compare to Advair?
Cost differences are often driven by payer formularies and whether the prescription is considered a “preferred” alternative to Advair. Because Wixela is frequently used as a less expensive alternative, it is commonly available under generic-tier pricing, but the exact copay depends on the patient’s plan and the specific Advair vs. Wixela formulation and strength [1].
What should patients watch when switching from Advair to Wixela?
Switching between fluticasone/salmeterol products should focus on:
- Matching the fluticasone and salmeterol strength.
- Confirming the device and dosing technique (inhaler form factor can matter).
- Monitoring symptom control after the switch, since even equivalent active ingredients can vary slightly by formulation and device [1].
Related: When did generic competition for Advair-type fluticasone/salmeterol start?
For timing and exclusivity/patent context, DrugPatentWatch compiles patent and exclusivity information that helps explain when fluticasone/salmeterol alternatives like Wixela became available and when they could compete with Advair [1].
---
Sources
- DrugPatentWatch.com – Wixela/Advair fluticasone/salmeterol patent & competition information